Amylyx Pharmaceuticals (AMLX) Current Leases (2022 - 2026)

Amylyx Pharmaceuticals' Current Leases history runs 5 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• On a quarterly basis, Current Leases rose 9.48% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a 9.48% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, down 17.06% from the prior year.
• Current Leases slipped to $1.2 million in Q1 2026 per AMLX's latest filing, from $1.3 million in the prior quarter.
• Across five years, Current Leases topped out at $2.4 million in Q2 2024 and bottomed at $665000.0 in Q2 2025.
• The 5-year median for Current Leases is $2.0 million (2024), against an average of $1.7 million.
• Across the five-year window, Current Leases surged 48.97% in 2023 and slumped 71.93% in 2025, its largest moves.
• Year by year, Current Leases stood at $2.0 million in 2022, then rose by 10.64% to $2.3 million in 2023, then tumbled by 32.74% to $1.5 million in 2024, then dropped by 17.06% to $1.3 million in 2025, then decreased by 8.26% to $1.2 million in 2026.
• Per Business Quant, the three latest AMLX Current Leases figures stand at $1.2 million (Q1 2026), $1.3 million (Q4 2025), and $981000.0 (Q3 2025).